Data Transfer Section
A focused Data Transfer section documents the controlled movement of trial data between systems or organizations, including security, verification, reconciliation, and traceability. It complements rather than replaces the broader Data Management section.
A Data Transfer section explains how trial data move between systems or parties, how transfers are protected and checked, and how traceability is maintained.
Key details
Important caveats
Scope Boundary
Keep transfer/exchange/migration controls separate from the broader lifecycle Data Management plan and from statistical analysis. Exact technical controls depend on the systems and applicable requirements.
Further guidance
Content
State the sending and receiving systems/parties, transfer method, security and confidentiality controls, validation or verification checks, reconciliation, error handling, and traceability of transfer or migration.
Purpose
Show that moving data does not break its integrity, confidentiality, completeness, or auditability.
Sources and evidence
Sources are shown with the role they play in this guide. Historical or style-sensitive claims are kept within the evidence boundary described above.
- E6(R3) Good Clinical Practice Guidance for Industry — September 2025 (opens in a new tab)U.S. Food and Drug Administration · Current ICH E6(R3) GCP guidance on investigator oversight, training/delegation, participant withdrawal, investigational-product accountability, site close-out, essential records, and insurance/indemnification
- E6(R3) Good Clinical Practice (GCP) — September 2025 (opens in a new tab)U.S. Food and Drug Administration · Current FDA final-guidance overview for ICH E6(R3), including quality by design, risk-based quality management, technology, proportionality, and clarified sponsor/investigator responsibilities